May 15, 2014
CTI Clinical Trial and Consulting Services to Attend Israel Innovation Conference (MIXiii) with REDI Cincinnati
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ May 15, 2014]
CTI Clinical Trial and Consulting Services (CTI) announces that they will attend the Israel Innovation Conference as part of the Regional Economic Development Initiative (REDI) Cincinnati group. The conference will be held in Tel Aviv, Israel May 20-22, 2014. The conference will be the first in the world where Biomed and High-tech industries will hold conferences in conjunction with one another.
“We currently work with over 70 global pharmaceutical and biotechnology companies, both with locations and projects located in Israel,” according to Lynn Fallon, President. “Israel has an extraordinarily well educated workforce, which bodes well for clinical research and innovation in medicine. With advances in fields such as regenerative medicine, geographies like Israel will become increasingly important for future studies and drug development initiatives.”
According to the Israel Innovation Conference, “the Biomed and High-tech conferences to be run side-by-side; each exhibiting its own sectors and activities in separate venues, with the audience free to move from one location to the other without limitation. The Biomed and High-tech venues will include lectures, company presentations and exhibitions. While each event will cater to the participants of its respective agenda, the event will also include joint sessions covering topics of mutual interest to the entire advanced technology industries including: perspectives of innovation and R&D policy and the convergence of technologies between High-tech and Biomed and other factors of the Israeli eco-sector. Previous successful conferences hosted over 7,000 industry players, engineers and scientists with approximately 1,500 participants from over 45 countries and an excess of 4,500 one-on-one meetings.”
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.